TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3177433
Drug: r‐HuEPO 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO 150 unit/kg intravenously three times weekly
Study: 3177433
Drug: r‐HuEPO 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO 50 unit/kg intravenously three times weekly
Study: 3177433
Drug: r‐HuEPO 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO 100 unit/kg intravenously three times weekly
Study: 3177433
Drug: r‐HuEPO (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO (all doses)
Study: 28329863
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (n = 228)
Study: 24388167
Drug: Dinaciclib (IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (IV, 50 mg/m2)
Study: 24388167
Drug: Erlotinib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (oral, 150 mg)
Study: 22486141
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg tablets twice a day for one week)
Study: 22486141
Drug: Placebo (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablets with the same dosage as sildenafil)
Study: 8917247
Drug: Clarithromycin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 10 mg/kg per day, twice a day for 7 days
Study: 8917247
Drug: Azithromycin, 10
Normalized name: Azithromycin, 100 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 10 mg/kg per day, once a day for 5 days
Study: 1899732
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid treatment (0.5 g solumedrol) before or at the same time as the first OKT3 injection
Study: 1899732
Drug: High-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroid treatment (0.5 g solumedrol) before the first OKT3 injection
Study: 7040581
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg oral dose
Study: 26716866
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 μg kg(‐1) loading dose over 10 min followed by 0.5 μg kg(‐1) h(‐1) during one-lung ventilation)
Study: 8584682
Drug: Fluspirilene 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluspirilene 0.5 mg per week
Study: 8584682
Drug: Fluspirilene 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluspirilene 1.0 mg per week
Study: 8584682
Drug: Fluspirilene 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluspirilene 1.5 mg per week
Study: 8584682
Drug: Test therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test therapy (initial response after 2 weeks)
Study: 637427
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (20 g of crude fiber)
Study: 637427
Drug: Low-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber diet (3 g of crude fiber)
Study: 31318075
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy with lenient definitions of remission
Study: 31318075
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy with stringent definitions of remission
Study: 19458055
Drug: Satraplatin administered
Normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satraplatin administered orally at 80 mg/m² once daily for 5 consecutive days every 5 weeks (fasted state)
Study: 19458055
Drug: Satraplatin administered
Normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satraplatin administered in fed state on day 1 and day 5 of cycle 1
Study: 19458055
Drug: Satraplatin administered
Normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satraplatin administered in fasted state for subsequent cycles
Study: 15641642
Drug: Acute poisonings
Normalized name: poison ivy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute poisonings via inhalation
Study: 15641642
Drug: Pharmaceutical poisons
Normalized name: poison ivy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical poisons
Study: 11391226
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day RAD
Study: 11391226
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day RAD
Study: 11391226
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day RAD
Study: 9266292
Drug: Palliative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative physical treatment
Study: 2878953
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg orally
Study: 2878953
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg orally
Study: 30114973
Drug: Isometric leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometric leg press training at L-MTU (knee angle 85°)
Study: 30114973
Drug: Both training
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both training groups (S-MTU and L-MTU)
Study: 20347079
Drug: Crinone vaginal
Normalized name: Crinone Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone vaginal gel
Study: 18541303
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (0.59+/‐0.07 g/kg body weight)
Study: 10962113
Drug: Hyperglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemic clamp at 10 mmol/l in non-diabetic twins
Study: 23859673
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg IV qd followed by 400 mg PO qd
Study: 23859673
Drug: Ampicillin-sulbactam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam 1.5 g IV qid followed by 750 mg PO q12h
Study: 23859673
Drug: Ampicillin-sulbactam therapy
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam therapy
Study: 20556561
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg + Hydrochlorothiazide 12.5 mg
Study: 8971294
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g sucralfate
Study: 27040041
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg every 8 hours for 2 months)
Study: 25400056
Drug: Photodynamic antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic antimicrobial therapy with Fufanghuangbai liquid wet dressing and semiconductor laser irradiation (20 min twice daily for 7 days)
Study: 23715447
Drug: Intraligamentous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentous injections with 4% articaine with epinephrine
Study: 7026344
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g/day (short-term)
Study: 7026344
Drug: Pirenzepine 75
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 75 mg/day (short-term)
Study: 7026344
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg at bedtime (long-term)
Study: 7026344
Drug: Pirenzepine 30
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 30 mg at bedtime (long-term)
Study: 26553006
Drug: Phytosterols and
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols and inulin-enriched soymilk (2 g/day of phytosterols and 10 g/day of inulin)
Study: 19688627
Drug: Resistant Starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant Starch (RS) 25 g daily for 14 days
Study: 19688627
Drug: Wheat Bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat Bran (WB) 25 g daily for 14 days
Study: 8988907
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn as zinc methionine
Study: 8988907
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn + 20 mg Fe
Study: 8506732
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (5 x 2 Gy)
Study: 8506732
Drug: High-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiotherapy (10 x 2 Gy or 5 x 3.5 Gy)
Study: 8506732
Drug: Low-dose vs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vs High-dose radiotherapy
Study: 3651109
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 100 mg t.i.d. for 120 days
Study: 29984567
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) based on NeckPix©, 4 sessions, 1-week duration
Study: 29984567
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) based on Tampa Scale of Kinesiophobia (TSK), 4 sessions, 1-week duration
Study: 18314433
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20‐40 mg)
Study: 18314433
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to venlafaxine (150‐225 mg)
Study: 18314433
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to a different SSRI plus cognitive behavioral therapy
Study: 18314433
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to venlafaxine plus cognitive behavioral therapy
Study: 18314433
Drug: Medication switch
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication switch alone
Study: 12202662
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 mg/m²/d) and LV (90 mg/d) for 28 days every 35 days
Study: 12202662
Drug: 5-FU (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (425 mg/m²/d) and LV (20 mg/m²/d) IV for 5 days every 35 days
Study: 10599909
Drug: Full-mouth scaling
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth scaling plus systemic metronidazole and amoxicillin and supragingival irrigation with chlorhexidine digluconate
Study: 7495241
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and multimineral supplements
Study: 6130074
Drug: Alcohol (1
Normalized name: POLYVINYL ALCOHOL (18000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1 g/kg) with Buspirone
Study: 30995972
Drug: Atrasentan 0·75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0·75 mg orally daily
Study: 30768615
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) mass drug administration (MDA)
Study: 28103942
Drug: Fipronil/(S)-methoprene combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fipronil/(S)-methoprene combination
Study: 23173698
Drug: Lead-in twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lead-in twice-daily interferon-β/ribavirin therapy (IFN-β)
Study: 23173698
Drug: PEG-IFN/ribavirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFN/ribavirin therapy (PEG)
Study: 19568011
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BtX‐A) injection
Study: 19568011
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline solution (placebo)
Study: 11711490
Drug: Estrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen supplementation (estradiol valerate 1 mg daily; n=7)
Study: 2889654
Drug: Betaxolol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.5% Ophthalmic Solution
Study: 28746977
Drug: Adjuvant fluorouracil/folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant fluorouracil/folinic acid (FUFA) chemotherapy
Study: 27388615
Drug: losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 100 mg once daily
Study: 27388615
Drug: spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: spironolactone 25 mg once daily
Study: 23640393
Drug: BOMP (bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOMP (bleomycin 7 mg days 1‐5, vincristine 0.7 mg m(‐2) day 5, mitomycin 7 mg m(‐2) day 5, cisplatin 14 mg m(‐2) days 1‐5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group)
Study: 20689583
Drug: Dihydroartemisinin-piperaquine (DHA/PQP);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DHA/PQP); adults: 40 mg/320 mg; children: 20 mg/160 mg; n = 769
Study: 20689583
Drug: Artesunate-mefloquine (AS+MQ);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine (AS+MQ); AS: 50 mg, MQ: 250 mg; n = 381
Study: 14552594
Drug: 0.2% brimonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% brimonidine eye drops given twice daily for 30 days
Study: 31967736
Drug: Collagen combination
Normalized name: collagen, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen combination material (collagen cone and collagen membrane)
Study: 28088030
Drug: metformin 500mg
Normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 500mg bid
Study: 28088030
Drug: metformin 1000mg
Normalized name: METFORMIN 1000MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 1000mg bid
Study: 28088030
Drug: linagliptin 2.5mg/metformin
Normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 2.5mg/metformin 500mg bid
Study: 28088030
Drug: linagliptin 2.5mg/metformin
Normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 2.5mg/metformin 1000mg bid
Study: 28088030
Drug: linagliptin 2.5mg/metformin
Normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 2.5mg/metformin 1000mg bid (severe hyperglycemia group)
Study: 25414262
Drug: AL-IVM1 (AL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-IVM1 (AL plus single dose of ivermectin 200 µg/kg)
Study: 25414262
Drug: AL-IVM2 (AL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-IVM2 (AL plus repeated dose of ivermectin 200 µg/kg)
Study: 21809664
Drug: Systemic chemo-infusion
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemo-infusion with oxaliplatin (FOLFOX)
Study: 21809664
Drug: Regional chemo-infusion
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional chemo-infusion with irinotecan (FOLFIRI)
Study: 21809664
Drug: Systemic chemo-infusion
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemo-infusion
Study: 21809664
Drug: Regional chemo-infusion
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional chemo-infusion
Study: 19728751
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg once daily for 10 days followed by 10 mg once daily for 10 days, along with aspirin 75 mg daily
Study: 19728751
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg maintenance dosing
Study: 19728751
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg maintenance dosing
Study: 16961674
Drug: Specific anticoagulant
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific anticoagulant prescription forms
Study: 16146551
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 8-12 ng/mL (GI)
Study: 16146551
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 15-20 ng/mL (GII)
Study: 12966414
Drug: Irinotecan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 200 mg/m² i.v. (1-h infusion) on day 1, L-leucovorin 250 mg/m² i.v. (1-h infusion) plus 5-fluorouracil 850 mg/m² i.v. bolus on day 2 every 2 weeks (IRIFAFU)
Study: 10218721
Drug: Temocapril 20
Normalized name: temocapril
DrugBank: Temocapril (DB08836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril 20 mg daily (n = 19)
Study: 2095610
Drug: clobutinol syrup
Normalized name: clobutinol
DrugBank: Clobutinol (DB09004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clobutinol syrup (Silomat, Boehringer, Ingelheim)
Study: 508075
Drug: Positional feedback
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positional feedback stimulation training (PFST) in addition to conventional treatment
Study: 31591187
Drug: CDK4/6 inhibitor
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor palbociclib and fulvestrant
Study: 29641247
Drug: Capsella bursa‐pastoris
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsella bursa‐pastoris capsules (dosage: 2 capsules every 12 hours)
Study: 29641247
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg, dosage: 2 capsules every 8 hours) + placebo
Study: 29207980
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive behavior therapy (CaCBTp), 12 weekly sessions
Study: 29207980
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive behavior therapy (CaCBTp)
Study: 26255892
Drug: Cefepime and
Normalized name: cefepime and amikacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime and amoxicillin/clavulanic acid combination therapy
Study: 26255892
Drug: Tigecycline-based therapy
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline-based therapy
Study: 15990739
Drug: Endovascular implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular implantation of a Medtronic Talent stent graft adjunctive to best medical treatment
Study: 12551865
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg single oral dose)
Study: 10097929
Drug: Mix25 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix25 insulin (36 ± 4 U)
Study: 10097929
Drug: 30/70 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/70 insulin
Study: 8906292
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MAOIs-A/B with 5-HTP
Study: 1867971
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic prophylaxis
Study: 31088188
Drug: Nilvadipine 8
Normalized name: nilvadipine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 8 mg/day
Study: 25050518
Drug: Curcuminoids (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (1,500 mg/day in 3 divided doses; n=19)
Study: 24447437
Drug: Seven-valent pneumococcal
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-valent pneumococcal conjugate vaccine (PCV-7)
Study: 18604047
Drug: Esmolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1 mg/kg)
Study: 24858149
Drug: Labetalol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.25 mg/kg)
Study: 8342183
Drug: Intravenous glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycerol (500 mL of 10% glycerol in saline over 4 hours on 6 consecutive days)
Study: 8342183
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (saline)
Study: 25028357
Drug: IVB+TRP (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB+TRP (1.25 mg IVB combined with targeted retinal photocoagulation)
Study: 23084240
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 0.5 mg monthly (0.5q4)
Study: 23084240
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg monthly (2q4)
Study: 23084240
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg every 2 months after 3 initial monthly doses (2q8)
Study: 23084240
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab 0.5 mg (Rq4)
Study: 15770890
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and combined chemoradiation
Study: 15770890
Drug: Various combined
Normalized name: various combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation
Study: 15770890
Drug: Vaccines, antisense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccines, antisense therapy, and proteasome inhibitors
Study: 12579101
Drug: Heparin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (bolus of 1 mg/kg)
Study: 2177507
Drug: Systemic interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic interferon and/or podophyllin treatment